Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy

Antibody-drug conjugates (ADCs) represent one of the most successful therapeutic approaches introduced in clinical practice in the last few years. Loncastuximab tesirine (ADCT-402) is a CD19 targeting ADC, in which the antibody is conjugated through a protease cleavable dipeptide linker to a pyrrol...

Descripció completa

Dades bibliogràfiques

Autors principals:	Chiara Tarantelli, David Wald, Nicolas Munz, Filippo Spriano, Alessio Bruscaggin, Eleonora Cannas, Luciano Cascione, Eugenio Gaudio, Alberto J. Arribas, Shivaprasad Manjappa, Gaetanina Golino, Lorenzo Scalise, Maria Teresa Cacciapuoti, Emanuele Zucca, Anastasios Stathis, Giorgio Inghirami, Patrick H. van Berkel, Davide Rossi, Paolo F. Caimi, Francesca Zammarchi, Francesco Bertoni
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2024-05-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/11580
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!